<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="syndrome coronavirus 2 (SARS-CoV-2) continues to sweep the world, causing" exact="infection" post="of millions and death of hundreds of thousands. The"/>
 <result pre="the virus structures, transmission characteristics, clinical symptoms, diagnosis, pathological changes," exact="treatment" post="and prevention of the two kinds of viruses, CoVs"/>
 <result pre="diseases [4,5]. It is necessary to investigate whether the simultaneous" exact="prevalence" post="of SARS-CoV-2 and other respiratory viruses, such as IAVs,"/>
 <result pre="addition, because the clinical symptoms caused by CoVs and IAVs" exact="infection" post="are very similar to each other [6], it will"/>
 <result pre="it will bring further challenges to clinicians in the timely" exact="diagnosis" post="and treatment of patients. This article will summarize and"/>
 <result pre="bring further challenges to clinicians in the timely diagnosis and" exact="treatment" post="of patients. This article will summarize and compare the"/>
 <result pre="the breaking of epidemics in future. 3 Clinical symptoms and" exact="diagnosis" post="The major clinical symptoms are summarized in TableÂ 2"/>
 <result pre="the early stage of disease onset, the cases with the" exact="infection" post="of different viruses mostly developed the same clinical symptoms"/>
 <result pre="dehydrogenase, and lymphocytopenia. In addition, three HPCoVs and H7N9 IAV" exact="infection" post="usually showed ground glass pneumonia. MERS-CoV, SARS-CoV, H7N9 IAV,"/>
 <result pre="more heart failure. The critical patient ratio of the HPHTs" exact="infection" post="can be 10%â€&quot;70% after 2â€&quot;10 days of the disease"/>
 <result pre="extracts. Then the viral RNAs can be directly identified by" exact="reverse transcription polymerase chain reaction" post="(RT-PCR) based methods, and the virus specific antibodies can"/>
 <result pre="the viral RNAs can be directly identified by reverse transcription" exact="polymerase chain reaction" post="(RT-PCR) based methods, and the virus specific antibodies can"/>
 <result pre="coronavirus, it is necessary to develop rapid and simple differential" exact="diagnosis" post="technologies and methods for identification of IAVs and CoVs."/>
 <result pre="like interferons etc. However, there are no specific drugs for" exact="treatment" post="of CoVs infection. Most often used for treatment of"/>
 <result pre="drugs for treatment of CoVs infection. Most often used for" exact="treatment" post="of SARS and MERS are ribavirin and lopinavir/ritonavir. Ribavirin"/>
 <result pre="used in combination with interferons to treat chronic hepatitis C" exact="infection" post="[108]. Lopinavir and ritonavir are two protease inhibitors previously"/>
 <result pre="Gilead Science, a nucleoside analog that mimics adenosine for previously" exact="treatment" post="of the Ebola virus infection [110]. Health authorities in"/>
 <result pre="that mimics adenosine for previously treatment of the Ebola virus" exact="infection" post="[110]. Health authorities in China have initiated clinical trials"/>
 <result pre="Research (INSERM) also evaluated the effect of remdesivir and other" exact="treatment" post="on COVID-19 patients [112]. Another promising drug is chloroquine"/>
 <result pre="the Chinese medicine formulate were also recommended by China for" exact="treatment" post="of COVID-19 [116]. Currently, for clinical treatment of influenza"/>
 <result pre="by China for treatment of COVID-19 [116]. Currently, for clinical" exact="treatment" post="of influenza infection, there are only three classes of"/>
 <result pre="has been reported frequently that they are ineffective in clinical" exact="treatment" post="due to drug resistance of almost all currently circulating"/>
 <result pre="WHO as the first choice of anti-influenza drugs for the" exact="treatment" post="or prophylaxis of influenza [118]. Until now, the neuraminidase"/>
 <result pre="inhibitors (NAIs) are still the most ideal reagents for clinical" exact="treatment" post="[120]. NAIs can prevent the hydrolytic activity of neuraminidase"/>
 <result pre="the combination of oseltamivir and probenecid may be an important" exact="treatment" post="option for severe patients. Balxavir marboxil, with a brand"/>
 <result pre="of virus mRNA transcription and effectively prevent influenza A virus" exact="infection" post="[[125], [126], [127]]. The antiviral spectrum of Xofloza includes"/>
 <result pre="in clinical development stage or partly approved for influenza virus" exact="infection" post="[[138], [139], [140]]. Considering the antigen drift and shift"/>
 <result pre="to HA stem domain, which may be useful for the" exact="treatment" post="of severe influenza disease [144]. 6 Prevention There are"/>
 <result pre="has the ability to induce neutralizing antibodies to stop virus" exact="infection" post="[145,146], which shines light on SARS-CoV-2 vaccine study. For"/>
 <result pre="are no specific and effective drugs or vaccines for the" exact="treatment" post="and prevention of CoVs. However, thanks to cliniciansâ€™ and"/>
 <result pre="efforts worldwide, some promising progress has been made in the" exact="treatment" post="of the diseases. Although there are some drugs and"/>
 <result pre="diseases. Although there are some drugs and vaccines for the" exact="treatment" post="and prevention of IAVs, it is still necessary to"/>
 <result pre="necessary to further research and develop more effective methods of" exact="treatment" post="and prevention to better control the influenza epidemic. Declaration"/>
 <result pre="importance for designing SARS vaccinesVirology3342005748215749124 10XiaS.LiuM.WangC.XuW.LanQ.FengS.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
 <result pre="evidence to detect antigenic driftVaccine29Suppl 22011B42B4821757103 39WuX.XiaoL.LiL.Research progress on human" exact="infection" post="with avian influenza H7N9Front Med14202082031989396 40SunY.CaoY.LiZ.BaiT.ZhangH.HuS.X.Cross-neutralizing anti-hemagglutinin antibodies isolated"/>
 <result pre="human infections by avian influenza A(H7N9) virusClin Infect Dis5720131449145723943822 67YuH.CowlingB.J.FengL.LauE.H.LiaoQ.TsangT.K.Human" exact="infection" post="with avian influenza A H7N9 virus: an assessment of"/>
 <result pre="One82013e73362 70PoepplW.HellM.HerknerH.StoiserB.FritscheG.Schurz-BamiehN.Clinical aspects of 2009 pandemic influenza A (H1N1) virus" exact="infection" post="in AustriaInfection39201134135221544585 71PatelM.DennisA.FlutterC.KhanZ.Pandemic (H1N1) 2009 influenzaBr J Anaesth104201012814220053625 72KhandakerG.DierigA.RashidH.KingC.HeronL.BooyR.Systematic"/>
 <result pre="humansJÂ Clin Virol45200916917319540800 75LiemN.T.TungC.V.HienN.D.HienT.T.ChauN.Q.LongH.T.Clinical features of human influenza A (H5N1)" exact="infection" post="in Vietnam: 2004-2006Clin Infect Dis4820091639164619435433 76HuiD.S.Review of clinical symptoms"/>
 <result pre="human cases of highly pathogenic avian influenza A (H5N1) virus" exact="infection" post="in ChinaPloS One32008e298518716658 78ZhangS.F.TuoJ.L.HuangX.B.ZhuX.ZhangD.M.ZhouK.Epidemiology characteristics of human coronaviruses in"/>
 <result pre="One32008e298518716658 78ZhangS.F.TuoJ.L.HuangX.B.ZhuX.ZhangD.M.ZhouK.Epidemiology characteristics of human coronaviruses in patients with respiratory" exact="infection" post="symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in"/>
 <result pre="2004-2005 through 2007-2008Influenza Other Respir Viruses62012374321668663 83RogoL.D.RezaeiF.MarashiS.M.YekaninejadM.S.NaseriM.GhavamiN.Seasonal influenza A/H3N2 virus" exact="infection" post="and IL-1Beta, IL-10, IL-17, and IL-28 polymorphisms in Iranian"/>
 <result pre="of a fatal case of Middle East respiratory syndrome coronavirus" exact="infection" post="in the United Arab Emirates, April 2014Am J Pathol186201665265826857507"/>
 <result pre="study of 8 autopsy cases from SingaporeHum Pathol34200374374814506633 93GuJ.GongE.ZhangB.ZhengJ.GaoZ.ZhongY.Multiple organ" exact="infection" post="and the pathogenesis of SARSJÂ Exp Med202200541542416043521 94FengY.HuL.LuS.ChenQ.ZhengY.ZengD.Molecular pathology"/>
 <result pre="virology findings in cases of fatal influenza A H1N1 virus" exact="infection" post="in 2009-2010Histopathology60201232633522211291 97MauadT.HajjarL.A.CallegariG.D.da SilvaL.F.SchoutD.GalasF.R.Lung pathology in fatal novel human"/>
 <result pre="100KortewegC.GuJ.Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1)" exact="infection" post="in humansAm J Pathol17220081155117018403604 101UiprasertkulM.KitphatiR.PuthavathanaP.KriwongR.KongchanagulA.UngchusakK.Apoptosis and pathogenesis of avian"/>
 <result pre="community-acquired pneumoniaJÂ Infect Dis19220051898190716267760 104VabretA.MourezT.GouarinS.PetitjeanJ.FreymuthF.An outbreak of coronavirus OC43 respiratory" exact="infection" post="in Normandy, FranceClin Infect Dis36200398598912684910 105PeneF.MerlatA.VabretA.RozenbergF.BuzynA.DreyfusF.Coronavirus 229E-related pneumonia in"/>
 <result pre="review of clinical trials utilizing chloroquine and hydroxychloroquine as a" exact="treatment" post="for COVID-19Acad Emerg Med202010.1111/acem.14005[online ahead of print] 116ChanK.W.WongV.T.TangS.C.W.COVID-19: an"/>
 <result pre="coronavirus diseaseAm J Chin Med202012632054304 117PizzornoA.PadeyB.TerrierO.Rosa-CalatravaM.Drug repurposing approaches for the" exact="treatment" post="of influenza viral infection: reviving old drugs to fight"/>
 <result pre="126LockeS.C.SplawnL.M.ChoJ.C.Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the" exact="treatment" post="of acute uncomplicated influenzaDrugs Today55201935936631250840 127KoszalkaP.TilmanisD.RoeM.VijaykrishnaD.HurtA.C.Baloxavir marboxil susceptibility of"/>
 <result pre="from the Asia-Pacific, 2012-2018Antivir Res1642019919630771405 128NgK.E.Xofluza (baloxavir marboxil) for the" exact="treatment" post="of acute uncomplicated influenzaPÂ T44201991130675086 129FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad"/>
 <result pre="Pharmacol1442017355128774731 137ShenX.T.ZhangX.X.LiuS.W.Novel hemagglutinin-based influenza virus inhibitorsJÂ Thorac Dis52013S149S15923977436 138SalvatoreM.SatlinM.J.JacobsS.E.JenkinsS.G.SchuetzA.N.MossR.B.DAS181 for" exact="treatment" post="of parainfluenza virus infections in hematopoietic stem cell transplant"/>
 <result pre="transplant recipients at a single centerBiol Blood Marrow Transplant22201696597026904972 139DhakalB.Dâ€™SouzaA.PasquiniM.SaberW.FenskeT.S.MossR.B.DAS181" exact="treatment" post="of severe parainfluenza virus 3 pneumonia in allogeneic hematopoietic"/>
</results>
